Why some companies may not be offering coverage for GLP-1 weight loss drugs
Corporate insurance coverage for GLP-1 weight-loss drugs is declining as companies like PepsiCo remove these benefits to manage pharmacy costs.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
GLP-1 coverage fell from 72% to 60% as some companies stopped offering coverage for weight-loss drugs, including PepsiCo. Pharmacy benefits became a stop-loss decision for employers.
Epilogue added 76d ago, after coverage quieted.
The brief
A trend of decreasing insurance coverage for GLP-1 weight-loss medications is emerging across the corporate sector. According to a report from 24/7 Wall St., coverage for these drugs has fallen from 72% to 60%. This shift is highlighted by a specific move from PepsiCo, which Bloomberg.com reports has scrapped coverage of weight-loss drugs for its employees. The current landscape suggests a potential obstacle for the weight-loss boom associated with pharmaceutical companies like Eli Lilly, as more employers reconsider the sustainability of these specific benefit plans. Coverage of this trend is being tracked by several outlets including ABC News, which is examining why some companies may no longer offer this coverage, and Bloomberg.com. The reporting emphasizes the financial pressures on employers and the resulting changes in benefit structures.
HR Executive has further detailed the operational side of this shift, noting that pharmacy benefits are now being treated as a stop-loss decision. This indicates that the high cost of these medications is forcing a strategic pivot in how companies manage their insurance risks and employee health expenditures. The context for this shift involves the rapid rise in popularity and adoption of GLP-1 medications. While these drugs have seen a massive surge in use, the financial burden on the providers of those benefits has increased. The decline from 72% to 60% in coverage mentioned by 24/7 Wall St. demonstrates a broader market correction. Devdiscourse has also noted these developments through a Reuters Health News Summary, signaling that the issue is being monitored by global health and business news organizations due to the scale of the pharmaceutical market involved.
Future developments to watch include whether more major corporations follow the example set by PepsiCo in removing weight-loss drug coverage. The situation remains fluid as companies balance employee health demands with the financial realities of pharmacy benefits. Observers are looking to see if the 'insurance wall' mentioned by 24/7 Wall St. will continue to rise, potentially impacting the growth trajectories of manufacturers like Eli Lilly. The transition of pharmacy benefits into stop-loss decisions suggests that the industry is moving toward a more restrictive model for high-cost specialty medications.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 77d ago.
Quick answers
Which company has recently stopped covering weight-loss drugs?
Bloomberg.com reports that PepsiCo has scrapped coverage of weight-loss drugs for its employees.
How much has GLP-1 coverage declined according to reports?
According to 24/7 Wall St., GLP-1 coverage fell from 72% to 60%.
What is the new approach to pharmacy benefits mentioned in the coverage?
HR Executive reports that pharmacy benefits are now being treated as a stop-loss decision.
Coverage (5)
- GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall? 24/7 Wall St. · 80d ago
- Why pharmacy benefits are now a stop-loss decision HR Executive · 80d ago
- Reuters Health News Summary Devdiscourse · 80d ago
- PepsiCo Scraps Coverage of Weight-Loss Drugs for Employees Bloomberg.com · 80d ago
- Why some companies may not be offering coverage for GLP-1 weight loss drugs ABC News - Breaking News, Latest News and Videos · 80d ago
Topics
Related trends
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Hundreds of children in England prescribed weight-loss jabs, figures show
New figures reveal hundreds of children in England, including under-12s, have been prescribed weight-loss jabs.